Title:
NEUROPROTECTIVE POLYPEPTIDE COMPOUND AND APPLICATION THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/006083
Kind Code:
A1
Abstract:
The present invention relates to the technical field of medicines, and disclosed are a neuroprotective polypeptide compound and an application thereof. The neuroprotective polypeptide compound comprises a polypeptide having the following chemical formula and a salt thereof: (M)m-(Lys-Leu-Ser-Ser-Ile-Glu/Asp-Ser/Thr-Asp/Glu-Val/Leu)-(N)n; m and n are integers from 0 to 3, but m and n are not zero at the same time; M is beta-Ala-His, beta-Ala-1-Methyl-His or beta-Ala-3-Methyl-His, and N is beta-Ala-His, beta-Ala-1-Methyl-His or beta-Ala-3-Methyl-His. An intravenous dosage of only 3 mg/kg can unexpectedly achieve a significant therapeutic effect, and achieve the same effect as NA1. The polypeptide compound can be used in combination with a hemolytic drug to provide a new possibility for the treatment of stroke.
Inventors:
LI JIANXIONG (CN)
Application Number:
PCT/CN2022/109048
Publication Date:
February 02, 2023
Filing Date:
July 29, 2022
Export Citation:
Assignee:
INNERSE ZHUHAI PHARMACEUTICAL CO LTD (CN)
International Classes:
C07K7/06; A61K38/08; A61K38/10; A61P9/12; A61P25/00; A61P25/16; A61P25/28; C07K7/08
Foreign References:
| CN106267149A | 2017-01-04 | |||
| CN113150065A | 2021-07-23 | |||
| CN103648518A | 2014-03-19 | |||
| CN106265594A | 2017-01-04 | |||
| CN113735938A | 2021-12-03 | |||
| US8536129B2 | 2013-09-17 | |||
| US8940699B2 | 2015-01-27 |
Other References:
MICHAEL D HILL ET AL.: "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomized controlled trial", LANCET, vol. 395, no. 10227, 2020, pages 878 - 887
MICHAEL D HILL ET AL.: "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial", LANCET, 20 February 2020 (2020-02-20)
MICHAEL D HILL ET AL.: "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial", LANCET, 20 February 2020 (2020-02-20)
Attorney, Agent or Firm:
BEIJING INTELLEGAL INTELLECTUAL PROPERTY AGENT LTD. (CN)
Download PDF: